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Context: Recent studies suggest that copy number varia-
tion in the human genome is extensive and may play an
important role in susceptibility to disease, including neu-
ropsychiatric disorders such as schizophrenia and autism.
Thepossible involvementof copynumbervariants (CNVs)
in bipolar disorder has received little attention to date.
Objectives:To determinewhether large (100000 base
pairs) and rare (found in1% of the population) CNVs
are associated with susceptibility to bipolar disorder and
to compare with findings in schizophrenia.
Design: A genome-wide survey of large, rare CNVs in a
case-control sample using a high-density microarray.
Setting:TheWellcomeTrustCaseControlConsortium.
Participants: There were 1697 cases of bipolar disor-
der and 2806 nonpsychiatric controls. All participants
were white UK residents.
Main OutcomeMeasures: Overall load of CNVs and
presence of rare CNVs.
Results: The burden of CNVs in bipolar disorder was
not increased compared with controls and was signifi-
cantly less than in schizophrenia cases. The CNVs pre-
viously implicated in the etiology of schizophrenia were
not more common in cases with bipolar disorder.
Conclusions: Schizophrenia and bipolar disorder dif-
fer with respect to CNV burden in general and associa-
tion with specific CNVs in particular. Our data are con-
sistent with the possibility that possession of large, rare
deletions may modify the phenotype in those at risk of
psychosis: those possessing such events are more likely
to be diagnosed as having schizophrenia, and those with-
out them are more likely to be diagnosed as having bi-
polar disorder.
Arch Gen Psychiatry. 2010;67(4):318-327
F AMILY, TWIN, AND ADOPTIONstudies have provided an im-pressive and consistent bodyof evidence supporting theexistence of genes that pre-
dispose to bipolar disorder, with a grada-
tion of risk as the genetic relatedness to a
proband diminishes.1 Large-scale col-
laborative genome-wide association stud-
ies (GWASs; hundreds of thousands of
single- nucleotide polymorphisms [SNPs]
studied in large numbers of cases and con-
trols) have started to deliver genome-
wide significant genetic associations for
bipolar disorder, thereby implicating com-
mon genetic polymorphisms in suscepti-
bility to illness.2 Ameta-analysis of GWAS
data from approximately 10 000 individu-
als has shown strong evidence for asso-
ciation with susceptibility to bipolar dis-
order at variants within 2 genes involved
in ion channel function: ANK3 (encod-
ing the protein ankyrin G) andCACNA1C
(encoding the -1C subunit of the L-type
voltage-gated calcium channel).3 In addi-
tion, other strong associations have been
reported in individual GWASs for several
other loci including PALB2, MYO5B, and
DGKH.4-6 Current evidence suggests that,
consistentwith findings inGWASs of non-
psychiatric disorders, a large number of
susceptibility lociwill be identified as larger
samples are studied.7
The focus of GWASs is identification
of common polymorphisms that influ-
ence susceptibility to illness. Another im-
portant source of genetic variation is ge-
nomic structural variation.8 It has recently
been recognized that structural genomic
variants are a common cause of genetic
variationinhumans,9andsuchvariantshave
been reported to substantially increase the
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risk of a number of neuropsychiatric phenotypes, includ-
ing autism, mental retardation, and schizophrenia.10-16
The overall load of copy number variants (CNVs) has
been shown to be greater in individuals with schizophre-
nia than controls.11,13,17 There is also convincing evidence
for association between schizophrenia and a number of
specific rareCNVs (1%population frequency), particu-
larly those at 22q11 (the velocardiofacial syndrome dele-
tion), 1q21.1, and15q13.3,12,13 and also to the class of rare
CNVs larger than 1megabase (Mb).14 Furthermore, some
specific CNVs associated with risk of schizophrenia con-
fer risk to multiple neuropsychiatric phenotypes, includ-
ingautism,attention-deficit/hyperactivitydisorder, andepi-
lepsy (eg, 1q21.1, 15q13.3, 22q11.2, and16p13.1).18,19 The
estimatedeffectsizes for theseCNVsaresubstantiallygreater
than those conferred by the SNPs discussed earlier. How-
ever, the typical effect sizes and population frequencies of
pathogenically relevant CNVs are not yet fully character-
ized, nor is the full extent towhichCNVs contribute to the
total populationvariance in riskof schizophrenia.Theonly
systematic study to date for bipolar disorder did not find
anyincrease inoverallCNVload,althoughtherewasanomi-
nally significant increase in“singleton”CNVs incases com-
pared with controls.20 There have been reports of specific
CNVs in individuals with bipolar disorder, but none has
addressed the question of whether CNVs show significant
overrepresentation in cases compared with controls.21,22
The aim of the present study was to investigate CNVs
in a large sampleof patientswithbipolar disorder (n=1697)
bymeans of data from a genemapping system (GeneChip
Human Mapping 500K Array Set; Affymetrix Inc, Santa
Clara, California), genotyped in theWellcomeTrust Case
Control Consortium (WTCCC) study.4We compared the
findings in our bipolar cases with those in a large sample
ofnonpsychiatric controls (n=2806) andalsowith a sample
of casesmeeting criteria for schizophrenia (n=440), all of
whom were genotyped as part of the WTCCC23 pipeline
with the use of identical methods.14
METHODS
SAMPLES
The bipolar disorder cases and the controls are those reported
by theWTCCC. A detailed description of the sample andmeth-
ods has been published previously.4
The bipolar disorder cases (n=1868) were older than 16
years, living in the United Kingdom, and of European white
ancestry. Clinical assessment included semistructured inter-
view and review of case notes. All patients received informa-
tion and signed a consent form for participation in genetic stud-
ies. Of those, 1697 individuals passed the quality control (QC)
filtering for the CNV analysis undertaken in the current study
(described in the next section). The diagnoses according to Re-
search Diagnostic Criteria were bipolar I disorder (n=1209),
schizoaffective disorder bipolar type (n=243), bipolar II dis-
order (n=156), and manic disorder (n=89).
The controls were all white UK residents and were collected
from2 sources: the 1958 birth cohort and theUKBlood Service.
It has previously been shown that these 2 control samples can
be combined for use as controls in genetic association studies
usingUKdisease samples, including thebipolardisorder sample.4
Of the2938 controls, 2806passed theQC filtering andwereused
for the CNV analysis (1411 individuals from the 1958 cohort
and 1395 from the UK Blood Service sample).
GENOTYPING AND CNV ANALYSIS
The DNA from case and control samples were genotyped with
the mapping array set at the laboratory of the manufacturer, as
previously described.4 The array set consists of 2 arrays: NspI
and StyI. On average, 250 000 SNPs were genotyped per array.
It is possible to infer data for the copynumber variation byusing
the intensity data of the SNP genotyping (.CEL files). For ex-
ploring the copy number variation by using the intensity data
from the SNP chip, Affymetrix Genotyping console v2.1 soft-
ware was used (http://www.affymetrix.com). Because the SNP
call rate is known to reflect sample quality, an initial basic QC
filter was applied to the data (using the default parameters of
the software) to exclude samples having an average SNP call
rate less than 93%.
For reference sets we used samples from the same processing
batches because using one reference set for all samples pro-
duced poor-quality data owing to systematic confounding ef-
fects. Because we sought to reduce to a minimum the false-
positive rate of calling CNVs, we applied the same stringent QC
filtering to the data that we used in our previous study of schizo-
phrenia.14 A deletion or duplication was called only if it was 100
kilobase (kb) or greater in length and comprised 10 ormore con-
secutive SNPs separately on each of the 2 arrays. The interquar-
tile range (IQR) of the log2 ratio was used to evaluate the quality
of the arrays for the copy number analyses. Samples with an IQR
greater than 0.40 (default parameter in the Affymetrix genotyp-
ing console v2.1 software) were excluded from the analysis.
Samples with an IQR greater than 0.40 produced more than 20
deletions and/or duplications (and 100 CNVs when the IQR
was0.50), suggesting that observations corresponding to 20 or
more CNV segments per personwere likely to be false-positives.
Therefore, samples with more than 20 segments were also ex-
cluded even if the observed IQR was 0.40 or less.
We accepted only deletions or duplications found indepen-
dently on both arrays, with the overlap of the segments iden-
tified by the StyI and the NspI arrays of 100 kb or greater. Seg-
ments were matched by means of a stand-alone program
developed in-house (available at http://x001.psycm.uwcm.ac
.uk/). We also excluded any CNVs that had very low SNP den-
sity (3 SNPs per 100 kb) because these tend to intersect low
copy repeats or “difficult-to-sequence” regions of the genome
and have an increased probability of being false-positives. Af-
ter these stringent QC filter criteria were applied, 1697 cases
and 2806 controls were retained for analysis.
Because there are difficulties in using this method to geno-
type common CNVs and consistent with recent studies using
this approach,13 commonCNVs (found in1% of the samples)
were excluded. Any CNVs that overlapped by more than 50%
of their length with common CNVs were also excluded. Using
PLINK24 version 1.05, all rare deletions and duplications that
remained after these criteria were listed in a custom track for
visualization in UCSC Genome Browser (University of Cali-
fornia, Santa Cruz; http://genome.ucsc.edu/), available at http:
//x004.psycm.uwcm.ac.uk/~detelina/.
We had previously performed a similar analysis on cases af-
fected with schizophrenia recruited from the same population
compared against the same set of WTCCC controls.14 As part
of that study, we validated 22 CNVs (most of them 1 Mb)
with a second platform (Human Genome CGHMicroarray Kit
44K; Agilent Technologies, Santa Clara, California). All vali-
dated correctly, reflecting our stringent filtering criteria and the
fact that each CNV had already been called independently by
2 arrays (StyI and NspI). We therefore did not attempt to vali-
date any CNVs in the current study.
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STATISTICAL ANALYSIS
The CNV association analyses were performed with PLINK24
version 1.05, obtained from http://pngu.mgh.harvard.edu
/~purcell/plink/.
The P values throughout this article are 2-tailed, based on
comparing the rate of CNVs in 2 independent samples (usu-
ally cases vs controls), and were derived with the use of 10 000
permutations. The genomic coordinates used in the study are
based on the March 2006 human genome sequence assembly
(UCSC Hg18, National Center for Biotechnology Information
build 36).
RESULTS
GLOBAL BURDEN OF CNVs
The total number of rare CNVs, and the corresponding
P value from the comparison between cases and controls,
are presented in Table 1. The rate of CNVs was not in-
creased in bipolar disorder cases comparedwith controls,
and there was even a nominally significant association in
theoppositedirection fordeletions(P=.01)(see thesupple-
mentary Results section for more details and a break-
down of these results according to CNV size in eTable 1;
available at: http://www.archgenpsychiatry.com).
Althoughwedidnot observe anoverall increase inCNV
burden in bipolar cases comparedwith controls, some in-
dividual CNVs were more common in cases than con-
trols (although none showed a significant association af-
ter correction formultiple testing). TheseCNVs are shown
in eTable 2. We did not observe any CNV events in cases
in the few regions inwhich there have been reports ofCNV
events in individuals with bipolar disorder (for details see
the supplementary Results section).
ANALYSIS OF SINGLETON CNVs
To test the recent report of an increased rate of rare single-
ton CNV events in bipolar disorder,20 we estimated the
global burden of single-occurrence deletions and single-
occurrence duplications. We found no difference be-
tween the proportion of cases and controls with single-
ton CNVs as a whole or when deletions and duplications
were considered separately (Table 2). The previous re-
port20 observed that singleton deletions were particu-
larly more common in cases with mania with an onset
of illness before age 18 years. In the 65 patients in our
sample with such an early age at onset, there was no dif-
ference in the rate of singleton CNVs compared with the
rest of the sample (data not shown).
Further details about the analysis of the singleton
events, and genes affected by CNVs only in cases, can be
found in the supplementary Results section (eTable 3).
ANALYSIS RESTRICTED TO CNVs
LARGER THAN 1 Mb
In our study of schizophrenia using the same methods
and samples from the same UK population,14 we ob-
served a significant increase in CNV load only for CNVs
larger than 1Mb.We therefore undertook an analysis of
this category in bipolar disorder (Table 3). There were
no significant differences between cases and controls; in-
deed, the trend was toward fewer CNV events in bipolar
disorder cases.
Whenwe compared our bipolar disorder cases against
our set of schizophrenia cases that had been examined for
this class of CNVs by the samemethods14 (n=440), we ob-
served a significant excess in the schizophrenia cases for
deletions and total CNVs (both P .001). There was also
a trend toward an excess of large duplications (P=.053)
in schizophrenia comparedwith bipolar disorder. The rate
of large CNVs in schizophrenia cases was approximately
5-foldhigher for deletions and approximately 2-foldhigher
forduplications comparedwith thebipolar cases (eTable1).
It should be noted that the P values reported herein for
the comparison between schizophrenia cases and con-
trols vary slightly from those published in our schizophre-





P ValueaNo. of CNVs No./Individual No. of CNVs No./Individual
Deletion 324 0.19 632 0.23 .01b
Duplication 538 0.32 901 0.32 .84
Total 862 0.51 1533 0.55 .10
aEmpirical 2-sided P value based on 10 000 permutations.
bNote that this significant result is for fewer CNVs in cases than controls.







per Case CNV per Control
Case to
Control Ratio P Value
Deletion 104 179 0.06 0.06 0.96 .77
Duplication 130 251 0.08 0.09 0.86 .17
Deletionduplication 203 355 0.12 0.13 0.95 .55
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nia report14 because of exclusion of schizoaffective cases
from the current analysis. Further details are provided in
the supplementary Results section.
ANALYSIS RESTRICTED TO CNVs
THAT DISRUPT GENES
Following a previous study of schizophrenia,13 we ex-
amined in the bipolar cases the burden of CNVs that de-
lete, duplicate, or disrupt genes (method described in the
supplementary Results section). This analysis was per-
formed for all CNVs and then for CNVs that occurred
only once in the data. Again, no significant differences
were found (data not shown). A list of all genes dis-
rupted in CNVs in cases that were not disrupted in any
controls is provided in eTable 4.
ANALYSIS OF CNVs PREVIOUSLY REPORTED
TO BE ASSOCIATED WITH RISK
OF SCHIZOPHRENIA
Table 4 shows the main chromosomal regions re-
ported to be associated with schizophrenia and the re-
spective number of the observed CNVs in the bipolar dis-
order cases and in the controls. We have included only
loci reported in multiple studies or with strong statisti-
cal support from at least 1 large study.
The total burden of these specific rare CNVs that have
been associated with risk of schizophrenia was not in-
creased in bipolar disorder cases compared with controls
(frequency per individual: cases, 0.010; controls, 0.016).
Only 2 regions showed a trend for overrepresentation in
cases. Duplications at 16p11.2 were found in 3 cases and
1 control, a 5-fold increase in frequency (0.2% vs 0.04%;
Fisher exact test, P=.15). One of these had arisen de novo
andwas not present in the proband’s father, who also had
bipolar disorder (see the supplementary Results section).
Two cases and no controls had duplications of 15q13.3,
deletion of which has been confirmed to confer suscepti-
bility to schizophrenia.12,13 More information on the loci
in Table 4 is given in the supplementary Results section.
COMMENT
We have undertaken a comparison of the occurrence of
rare CNVs in a large white UK set of bipolar cases and
controls using genome-wide SNP data generated within
theWTCCC study.4 In contrast to several recent reports
of an increased burden of rare CNVs, particularly large
deletions, in schizophrenia cases compared with con-
trols, we observed no such increase in bipolar disorder
cases, and there was even a trend toward a reduced rate
for deletions. Furthermore, direct comparison of our bi-
polar disorder cases with our set of schizophrenia cases
recruited from the same UK clinical population, as-
sessed by similar clinicalmethods and analyzed bymeans
of the same genotyping platform, QC filtering, and sta-
tistical methods, showed that deletions greater than 1Mb
were about 5 times more common in the schizophrenia
cases (P .001). Thus, our data demonstrate a signifi-
cant difference between bipolar disorder and schizophre-
nia with respect to global burden of rare and large CNVs.
In addition, we did not find evidence of even a trend
toward an increase in bipolar disorder in the frequency of
specific CNVs that have been reported to show a robust











Control Ratio P Value
Deletion 7 20 0.004 0.007 0.58 .24
Duplication 33 65 0.019 0.023 0.84 .47
Deletionduplication 40 85 0.024 0.030 0.78 .20
Table 4. CNVs Previously Implicated in Schizophrenia and Corresponding Findings in the Current Study
Locusa Type References Positionb Cases Controls
1q21.1c del 12, 13 chr1:144.9-146.3 1 dup 2 del; 2 dup
2p16.3 (NRXN1) del 11, 31, 32 chr2:50-51.3 0 4 del (various lengths)
7q34-36.1 del 33 chr7:145.6-148.7 0 0
15q11.2c del 12 chr15:20.31-20.78 3 del; 7 dup 14 del; 10 dup
15q13.3c del 12, 13 chr15:28.7-30.30 2 dup 0
16p11.2 dup 11 chr16:29.5-30.3 3 dup 3 del; 1 dup
17p12 del 14 chr17:14.0-15.4 1 dup 0
22q11.2c del 12-14, 34 chr22:17.2-19.8 0 8 dup
Total NA NA NA 3 del; 14 dup 23 del; 21 dup
Abbreviations: CNV, copy number variant; del, deletion; dup, duplication; NA, not applicable.
aLocus refers to the chromosome band.
bPosition refers to chromosome and physical location in megabases of DNA from the p terminus (thus, “chr1:144.9-146.3” designates the region of DNA
between 144.9 and 146.3 megabases from the p terminus of chromosome 1).
cNote that the current evidence for association of these loci with schizophrenia is strongest for 1q21.1, 15q11.2, 15q13.3, and 22q11.2 (where, for each,
significance approaches or exceeds P510−8).
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association with schizophrenia. It is important to recog-
nize that power to detect a significant association at any
specific rare CNV is low, although our power to detect the
joint association of the 4 robustly schizophrenia-
associated deletions (1q21.1, 15q11.2, 15q13.3, and
22q11.2) at P .05 exceeds 96%. It is of particular inter-
est that we observed no instances of a 22q11 deletion in
ourbipolar sample. In contrast, inourmuch smaller schizo-
phrenia sample14 we observed 2 such deletions. Thus, our
data do not support the hypothesis that 22q11 deletion
syndrome (associated with velocardiofacial syndrome) is
associated with bipolar disorder, as others have sug-
gested.27 The only locus implicated in schizophrenia that
showed a trend for overrepresentation in bipolar caseswas
duplication at 16p11.2, with a 5-fold increased rate over
controls, but this did not reach statistical significance.
Genetic epidemiology suggests the existence of some
genetic factors that confer risk to both schizophrenia and
bipolar disorder and others that confer relatively specific
risk to one or other of the dichotomous categories.35,36 A
recent study of approximately 10 000 individuals has pro-
vided strong evidence of association between bipolar dis-
order and SNPs within 2 genes involved in ion channel
function: ANK3 and CACNA1C.3 The SNP in CACNA1C
that was most strongly associated with bipolar disorder
shows a similar magnitude of association in UK schizo-
phrenia and unipolar depression samples.37 Thus, varia-
tion at this locus influences susceptibility across themood-
psychosis spectrum. A study of approximately 20 000
individuals has provided strong evidence of association be-
tween schizophrenia and an SNP within ZNF804A (en-
coding a protein of unknown function, but that, on the
basis of sequence similarity, may act as a transcription
factor).23 The same SNP in ZNF804A also showed evi-
dence of association with bipolar disorder,23 again dem-
onstrating that variation at this locus also has an effect on
illness susceptibility across the traditionaldiagnosticbound-
aries. Thus, for 2 of the recent strongly supported SNP as-
sociations that have been reported with the use of large
samples andGWASmethods, there is evidence of an over-
lap in susceptibility across the traditional kraepelinian di-
chotomy.Further recent support for the existenceof shared
genetic risk comes from the observationof overlapping sets
of genes showing gene-wide significance in a gene-based
analysis of genome-wide SNPdata for bipolar disorder and
schizophrenia.38 In contrast, theCNV findings to date sug-
gest that copy number variationmay have a relatively spe-
cific influence on susceptibility to illness that meets diag-
nostic criteria for schizophrenia.
This possibility has substantial face validity in that
CNVs are known to be associated with some persistent
neuropsychiatric phenotypes that are known to occur in,
or be risk factors for, illnesses that meet diagnostic cri-
teria for schizophrenia, includingmental retardation, epi-
lepsy, and autism.18,19 Thus, CNVs may predispose to
persistent brain dysfunctions that affect intellectual func-
tioning and personality development thatmaymodify ex-
pression of the phenotype in those who have a propen-
sity to develop psychoses.39,40
In our analyses, we found that the CNV burden was
lower in our bipolar disorder cases than controls, and this
differencewas statistically significantwhen deletionswere
considered separately (Table 1; P=.01). Because this find-
ing is not highly significant in the context ofmultiple test-
ing, it may well be a chance finding, and therefore we
consider that our data should be interpreted conserva-
tively as showing no increase in burden of CNVs in bi-
polar cases compared with controls.
To our knowledge, there has been only 1 previous sys-
tematic genome-wide CNV analysis in bipolar disorder20;
like the present study, it showed no increase in the total
burden of CNVs in cases compared with controls. How-
ever, our data do not replicate the finding of a significant
increase in singleton CNV events in bipolar cases com-
paredwith controls. Our study is larger than that of Zhang
et al,20 andpower exceeded95%todetect the reported effect
size at P .05. Power is obviously lower if there is a true,
but smaller, increase in singleton CNV burden or if our
stringent QC method resulted in our detecting a smaller
proportion of the relevant loci.With respect to very weak
effects, no single study can provide definitive results, and
therefore in this context a type II error in the present bi-
polar vs control analysis study cannot be fully dis-
counted. However, the findings of Zhang and colleagues
aremuchweaker than those reported inmuch smaller stud-
ies of schizophrenia and autism, and it is possible the re-
sults of that study represent a type I error because they
would not withstand correction for testingmultiple plau-
sible hypotheses concerning CNV size, type, and fre-
quency. Although additional studies will be required to
finally resolve this discrepancy, our study does provide
strong evidence that any contribution to bipolar disorder
from CNVs in the size range we tested for is significantly
smaller than it is to schizophrenia.
Although we have no evidence to support any spe-
cific locus, even single observations of occurrence of a
CNV in a disorder can ultimatelymake an important con-
tribution to understanding of disease pathogenesis, eg,
the observation of a rare deletion in the NRXN1 gene in
a proband with schizophrenia.31 To facilitate this, and
downstream meta-analyses, we presented the full list of
rare CNVs found in cases and controls in our supple-
mentary material.
The strengths of our study include the large sample
size, the rigorous QC filtering used, and our ability to
make direct comparisons between bipolar disorder and
schizophrenia cases that have been recruited from simi-
lar clinical populations and analyzed bymeans of the same
genotyping pipeline and statistical methods. Some im-
portant limitations are inherent in all studies of CNVs.
The first, as mentioned earlier, concerns power to de-
tect very small increases in CNV burden. Second, CNV
analyses using SNP data are not straightforward and re-
quire several analytic steps that are difficult to standard-
ize precisely across studies by different investigators. This
does not, however, affect comparisons across our own
bipolar disorder and schizophrenia samples. The geno-
typing platform used in the WTCCC study (Affymetrix
500K chip)was one of the earliest GWAS genotyping plat-
forms and, hence, has less resolution for CNVs than later
platforms. This has much less influence on large CNVs
(the focus of our study) but, because of this limitation,
we have not tested the contribution of smaller CNVs
(100 kb) to disease susceptibility. In the future, it will
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Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Re-
search, University of Cambridge; Niall C. Taylor, Department of Haematology, University of Cambridge; John A. Todd, Juvenile
Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cam-
bridge Institute for Medical Research, University of Cambridge; Neil M. Walker, Juvenile Diabetes Research Foundation/
Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Re-
search, University of Cambridge; Graham R. Walters, National Health Service Blood and Transplant, Southampton Centre,
Southampton, England; Nicholas A. Watkins, Department of Haematology, University of Cambridge, and National Health Ser-
vice Blood and Transplant, Cambridge Centre; and Thilo Winzer, Department of Haematology, University of Cambridge.
1958 Birth Cohort Controls
RichardW. Jones, Avon Longitudinal Study of Parents andChildren, University of Bristol, Bristol, England;Wendy L.McArdle
and Susan M. Ring, Avon Longitudinal Study of Parents and Children, University of Bristol; Marcus Pembrey, Avon Longi-
tudinal Study of Parents and Children, University of Bristol, and Institute of Child Health, University College London; and
David P. Strachan, Division of Community Health Services, St George’s University of London.
Bipolar Disorder
Aberdeen, Scotland: Gerome Breen and David M. St Clair, University of Aberdeen, Institute of Medical Sciences. Birmingham,
England: Sian Caesar, Katherine Gordon-Smith (also Department of PsychologicalMedicine, HenryWellcome Building, School
of Medicine, Cardiff University), and Lisa Jones, Department of Psychiatry, Division of Neuroscience, Birmingham Univer-
sity. Cardiff: Nick Craddock, Christine Fraser, Elaine K. Green, Detelina Grozeva, Marian L. Hamshere, Peter A. Holmans,
Ian R. Jones, George Kirov, Valentina Moskvina, Ivan Nikolov, Michael C. O’Donovan, and Michael J. Owen, Department of
Psychological Medicine, HenryWellcome Building, School of Medicine, Cardiff University. London: David A. Collier, Amanda
Elkin, Anne E. Farmer, Peter McGuffin, and Richard Williamson, Social, Genetic, and Developmental Psychiatry Center,
Institute of Psychiatry, King’s College London. Newcastle, England: I. Nicol Ferrier and Allan H. Young, School of Neurol-
ogy, Neurobiology, and Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne.
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Members of Wellcome Trust Case Control Consortium (continued)
Coronary Artery Disease
Leeds, England: Stephen G. Ball, Anthony J. Balmforth, Jennifer H. Barrett, D. Timothy Bishop, Alistair S. Hall, Mark M. Iles,
AzharMaqbool, and Nadira Yuldasheva, Leeds Institute of Genetics, Health, and Therapeutics and Leeds Institute of Molecular
Medicine, Faculty of Medicine and Health, University of Leeds. Leicester: Peter S. Braund, Richard J. Dixon, MassimoMangino,
Nilesh J. Samani, and Suzanne Stevens, Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital; and
Paul R. Burton, Martin D. Tobin, and John R. Thompson, Genetic Epidemiology Group, Department of Health Sciences, Uni-
versity of Leicester.
Crohn Disease
Cambridge: Francesca Bredin, Miles Parkes, and Mark Tremelling, Inflammatory Bowel Disease Research Group, Adden-
brooke’s Hospital, University of Cambridge. Edinburgh: Hazel Drummond, Charles W. Lees, Elaine R. Nimmo, and Jack Sat-
sangi, Gastrointestinal Unit, School of Molecular and Clinical Medicine, University of Edinburgh, Western General Hospi-
tal. London: Sheila A. Fisher, CathrynM. Lewis, Christopher G. Mathew, Clive M. Onnie, and Natalie J. Prescott, Department
of Medical and Molecular Genetics, King’s College London School of Medicine, Guy’s Hospital, London; Alastair Forbes,
Institute for Digestive Diseases, University College London Hospitals Trust; and Jeremy Sanderson, Department of Gastro-
enterology, Guy’s and St Thomas’ NHS (National Health Service) Foundation Trust, London.Newcastle: Jamie Barbour, John
C. Mansfield, M. Khalid Mohiuddin, and Catherine E. Todhunter, Department of Gastroenterology and Hepatology, Uni-
versity of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne. Oxford: Tariq Ahmad, Fraser R. Cum-
mings, and Derek P. Jewell, Gastroenterology Unit, Radcliffe Infirmary, University of Oxford.
Hypertension
Aberdeen: John Webster, Medicine and Therapeutics, Aberdeen Royal Infirmary, Foresterhill, Aberdeen. Cambridge: Morris
J. Brown, Clinical Pharmacology Unit and Diabetes and Inflammation Laboratory, University of Cambridge, Addenbrookes
Hospital, Cambridge; and David G. Clayton, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflam-
mation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge.
Evry, France: G. Mark Lathrop, Centre National de Genotypage. Glasgow, Scotland: John Connell and Anna Dominiczak,
British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow. Leicester: Nilesh J. Samani, De-
partment of Cardiovascular Sciences, University of Leicester, Glenfield Hospital. London: Carolina A. Braga Marcano, Bev-
erley Burke, Mark Caulfield, Richard Dobson, Johannie Gungadoo, Kate L. Lee, Patricia B. Munroe, Stephen J. Newhouse,
Abiodun Onipinla, Chris Wallace, and Mingzhan Xue, Clinical Pharmacology and Barts and The London Genome Centre,
William Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine. Oxford: Martin Farrall, Car-
diovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics.
Rheumatoid Arthritis
Anne Barton, Ian N. Bruce, Hannah Donovan, Steve Eyre, Paul D. Gilbert, Samantha L. Hider, Anne M. Hinks, Sally L. John,
Catherine Potter, Alan J. Silman, Deborah P. M. Symmons, Wendy Thomson, and Jane Worthington, arc Epidemiology Re-
search Unit, University of Manchester, Manchester, England.
Type 1 Diabetes
DavidG. Clayton, SarahNutland, Helen E. Stevens, JohnA. Todd, andNeilM.Walker, Juvenile Diabetes Research Foundation/
Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical
Research, University of Cambridge; David B. Dunger and Barry Widmer, Juvenile Diabetes Research Foundation/Wellcome
Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research,
University of Cambridge, and Department of Paediatrics, University of Cambridge, Addenbrooke’s Hospital, Cambridge.
Type 2 Diabetes
Exeter, England: Timothy M. Frayling, Rachel M. Freathy, Andrew T. Hattersley, Hana Lango, John R. B. Perry, and Michael
N. Weedon, Genetics of Complex Traits, Institute of Biomedical and Clinical Science, and Diabetes Genetics, Institute of
Biomedical and Clinical Science, Peninsula Medical School; and Beverley M. Shields, Diabetes Genetics, Institute of Bio-
medical and Clinical Science, PeninsulaMedical School. London: GrahamA. Hitman, Centre for Diabetes andMetabolicMedi-
cine, Barts and The London, Royal London Hospital. Newcastle: Mark Walker, Diabetes Research Group, School of Clinical
Medical Sciences, Newcastle University. Oxford: Kate S. Elliott, Cecilia M. Lindgren, Mark I. McCarthy, Nigel W. Rayner,
and Eleftheria Zeggini, Wellcome Trust Centre for Human Genetics and Oxford Centre for Diabetes, Endocrinology, and
Medicine, University of Oxford; Christopher J. Groves, Oxford Centre for Diabetes, Endocrinology, and Medicine, Univer-
sity of Oxford; and Nicholas J. Timpson,Wellcome Trust Centre for Human Genetics, University of Oxford, and the Medical
Research Council Centre for Causal Analyses in Translational Epidemiology, Bristol University.
Tuberculosis
Gambia: Melanie Newport and Giorgio Sirugo, Medical Research Council Laboratories, Fajara, the Gambia. Oxford: Adrian
V. S. Hill, Emily Lyons, and Fredrik Vannberg, Wellcome Trust Centre for Human Genetics, University of Oxford.
Ankylosing Spondylitis
Linda A. Bradbury and Jennifer J. Pointon, Diamantina Institute for Cancer, Immunology, andMetabolic Medicine, Princess Al-
exandraHospital, University ofQueensland,Woolloongabba,Queensland, Australia; Claire Farrar andPaulWordsworth, Botnar
Research Centre, University of Oxford; and Matthew A. Brown, Diamantina Institute for Cancer, Immunology, and Metabolic
Medicine, Princess Alexandra Hospital, University of Queensland, and Botnar Research Centre, University of Oxford.
(continued)
(REPRINTED) ARCH GEN PSYCHIATRY/VOL 67 (NO. 4), APR 2010 WWW.ARCHGENPSYCHIATRY.COM
324
©2010 American Medical Association. All rights reserved.
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 09/13/2015
Members of Wellcome Trust Case Control Consortium (continued)
Autoimmune Thyroid Disease
Jayne A. Franklyn, Stephen C. L. Gough, Joanne M. Heward, and Matthew J. Simmonds, Department of Medicine, Division
of Medical Sciences, Institute of Biomedical Research, University of Birmingham.
Breast Cancer
Nazneen Rahman and Sheila Seal, Section of Cancer Genetics, Institute of Cancer Research, Sutton, England; and Michael R.
Stratton, Section of Cancer Genetics, Institute of Cancer Research, Sutton, and Cancer Genome Project, The Wellcome Trust
Sanger Institute, Wellcome Trust Genome Campus.
Multiple Sclerosis
Maria Ban, Alastair Compston, An Goris, and Stephen J. Sawcer, Department of Clinical Neurosciences, University of Cam-
bridge, Addenbrooke’s Hospital, Cambridge.
Gambian Controls
Gambia: David Conway, Muminatou Jallow, Melanie Newport, and Giorgio Sirugo, Medical Research Council Laboratories.Ox-
ford: Kirk A. Rockett, Wellcome Trust Centre for Human Genetics, University of Oxford; and Dominic P. Kwiatkowski, Well-
come Trust Centre for Human Genetics, University of Oxford, and Wellcome Trust Sanger Institute, Wellcome Trust Genome
Campus.
DNA, Genotyping, Data Quality Control, and Informatics
Wellcome Trust Sanger Institute, Hinxton: Suzannah J. Bumpstead, Amy Chaney, Panos Deloukas, Kate Downes (also Juvenile
Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics,
Cambridge Institute forMedical Research, University of Cambridge), Mohammed J. R. Ghori, Rhian Gwilliam, Sarah E. Hunt,
Michael Inouye, Andrew Keniry, Emma King, RalphMcGinnis, Simon Potter, Rathi Ravindrarajah, PamelaWhittaker, Claire
Widden, and DavidWithers.Cambridge: Hin-Tak Leung, Sarah Nutland, Helen E. Stevens, John A. Todd, andNeil M.Walker,
Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Ge-
netics, Cambridge Institute for Medical Research, University of Cambridge.
Statistics
Cambridge: Doug Easton, Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge; and
David G. Clayton, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department
ofMedical Genetics, Cambridge Institute forMedical Research, University of Cambridge. Leicester: Paul R. Burton andMartin D.
Tobin, Genetic Epidemiology Group, Department of Health Sciences, University of Leicester. Oxford: Jeffrey C. Barrett, Lon R.
Cardon, David M. Evans, and Andrew P. Morris, Wellcome Trust Centre for Human Genetics, University of Oxford. Oxford:
Niall J. Cardin, Dan Davison, Teresa Ferreira, Ingeleif B. Hallgrimsdo´ttir, Bryan N. Howie, Jonathan L.Marchini, Joanne Pereira-
Gale, Chris C. A. Spencer, Zhan Su, Yik Ying Teo (alsoWellcomeTrust Centre for HumanGenetics, University of Oxford), Dam-
jan Vukcevic, and Peter Donnelly, Department of Statistics, University of Oxford.
Principal Investigators
David Bentley, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus (now with Illumina Cambridge, Ches-
terford Research Park, Little Chesterford, Nr Saffron Walden, Essex, England); Matthew A. Brown, Diamantina Institute for
Cancer, Immunology, and Metabolic Medicine, Princess Alexandra Hospital, University of Queensland, and Botnar Re-
search Centre, University of Oxford; Lon R. Cardon, Wellcome Trust Centre for Human Genetics, University of Oxford;
Mark Caulfield, Clinical Pharmacology and Barts and The London Genome Centre,WilliamHarvey Research Institute, Barts
and The London, Queen Mary’s School of Medicine; David G. Clayton, Juvenile Diabetes Research Foundation/Wellcome
Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research,
University of Cambridge; Alistair Compston, Department of Clinical Neurosciences, University of Cambridge, Adden-
brooke’s Hospital; Nick Craddock, Department of Psychological Medicine, Henry Wellcome Building, School of Medicine,
Cardiff University; Panos Deloukas, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus; Peter Donnelly,
Department of Statistics, University of Oxford; Martin Farrall, Cardiovascular Medicine, University of Oxford, Wellcome
Trust Centre for Human Genetics; Stephen C. L. Gough, Department of Medicine, Division of Medical Sciences, Institute of
Biomedical Research, University of Birmingham; Alistair S. Hall, Leeds Institute of Genetics, Health, and Therapeutics and
Leeds Institute of Molecular Medicine, Faculty of Medicine and Health, University of Leeds; Andrew T. Hattersley, Genetics
of Complex Traits and Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula Medical School; Adrian V.
S. Hill, Wellcome Trust Centre for Human Genetics, University of Oxford; Dominic P. Kwiatkowski, Wellcome Trust Cen-
tre for HumanGenetics, University of Oxford, andWellcome Trust Sanger Institute,Wellcome Trust GenomeCampus; Chris-
topher G. Mathew, Department of Medical and Molecular Genetics, King’s College London School of Medicine, Guy’s Hos-
pital; Mark I. McCarthy, Wellcome Trust Centre for Human Genetics and Oxford Centre for Diabetes, Endocrinology, and
Medicine, University of Oxford; Willem H. Ouwehand, Department of Haematology, University of Cambridge, and National
Health Service Blood and Transplant, Cambridge Centre; Miles Parkes, Inflammatory Bowel Disease Research Group, Ad-
denbrooke’s Hospital, University of Cambridge; Marcus Pembrey, Avon Longitudinal Study of Parents and Children, Uni-
versity of Bristol, and Institute of Child Health, University College London; Nazneen Rahman, Section of Cancer Genetics,
Institute of Cancer Research, Sutton; Nilesh J. Samani, Department of Cardiovascular Sciences, University of Leicester; Michael
R. Stratton, Section ofCancerGenetics, Institute of Cancer Research, Sutton, andCancerGenomeProject,WellcomeTrust Sanger
Institute, Wellcome Trust Genome Campus; John A. Todd, Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes
and Inflammation Laboratory, Department ofMedical Genetics, Cambridge Institute forMedical Research, University of Cam-
bridge; and Jane Worthington, arc Epidemiology Research Unit, University of Manchester.
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be important to undertake further studies that use much
higher-resolution platforms and that allow CNVs to be
called at similar levels of accuracy as SNPs to provide fur-
ther information about a wider spectrum of CNV sizes.
The number ofCNVs increases exponentiallywith smaller
CNV size,41 so most CNVs remain to be identified and
examined for association with disease.
Finally, CNV burden analysis alone cannot identify
specific risk factors; nevertheless, the approach we pre-
sent herein has proved pivotal in pointing to the involve-
ment of CNVs in schizophrenia and other disorders.
In conclusion, we have used genome-wide associa-
tion data to undertake a comparison of CNV burden in
a large sample of bipolar disorder cases, nonpsychiatric
controls, and schizophrenia cases. We found that CNV
load was not elevated in bipolar disorder compared with
controls and that deletions larger than 1 Mb were less
common in probands with bipolar disorder than in those
with schizophrenia. Our findings suggest that schizo-
phrenia and bipolar disorder differ with respect to CNV
burden in general and association with specific schizo-
phrenia-associated CNVs in particular.
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